Ikarian Capital, LLC Beam Therapeutics Inc. Transaction History
Ikarian Capital, LLC
- $573 Million
- Q3 2024
A detailed history of Ikarian Capital, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 360,000 shares of BEAM stock, worth $8.66 Million. This represents 0.97% of its overall portfolio holdings.
Number of Shares
360,000Holding current value
$8.66 Million% of portfolio
0.97%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BEAM
# of Institutions
236Shares Held
75.2MCall Options Held
438KPut Options Held
232K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$197 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.84MShares$189 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$184 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.53MShares$157 Million1.52% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$116 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.69B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...